Moneycontrol
SENSEX NIFTY
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > News - Dr Reddys Laboratories

Dr Reddys Laboratories

BSE: 500124|NSE: DRREDDY|ISIN: INE089A01023|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
May 26, 16:00
2411.70
-15.6 (-0.64%)
VOLUME 56,732
LIVE
NSE
May 26, 15:58
2414.40
-13.3 (-0.55%)
VOLUME 721,029
News on Dr Reddys Laboratories
Select Year: 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2000-2005
Positive on pharma; buy Dr Reddys, Cipla, Aurobindo: Rahul Arora 

4.24 pm | 26 May 2017 |  Source: CNBC-TV18

In an interview to CNBC-TV18, Rahul Arora, CEO at Nirmal Bang Institutional Equities, shared his views on various stocks and sectors....

Hold Dr Reddy's Laboratories; target of Rs 2450: Axis Direct

3.51 pm | 22 May 2017 |  Source: Moneycontrol.com

Axis Direct recommended hold rating on Dr Reddy's Laboratories with a target price of Rs 2450 in its research report dated May 18, 2017....

USFDA clears Dr Reddy's ovarian cancer generic sale

1.50 pm | 17 May 2017 |  Source: PTI

The approval from the US Food and Drug Administration (USFDA) for doxorubicin hydrochloride liposome intravenous injection is an outcome of extensive ...

Hold Dr Reddy’s Laboratories; target of Rs 2610: ICICI Direct

4.58 pm | 16 May 2017 |  Source: Moneycontrol.com

ICICI Direct recommended hold rating on Dr Reddy’s Laboratories with a target price of Rs 2610 in its research report dated May 15, 2017....

Stocks in the news: Dr Reddy's Lab, Infosys, Colgate, Skipper, Bata, Premier Explosives

8.18 am | 16 May 2017 |  Source: Moneycontrol.com

Dr Reddy's Laboratories | Infosys | Premier Explosives | Brigade Enterprises | Tata Motors | Colgate | JK Tyre | Bata India | Sutlej Textiles | Sk...

Dr Reddy's launches generic hepatitis C drug in India

4.59 pm | 15 May 2017 |  Source: PTI

Dr Reddy's Laboratories today said it has launched a generic version of Sofosbuvir 400 mg and Velpatasvir 100 mg fixed-dose combination, indicated...

Hold Dr. Reddys Laboratories; target of Rs 2660: Edelweiss

4.50 pm | 15 May 2017 |  Source: Moneycontrol.com

Edelweiss recommended hold rating on Dr. Reddys Laboratories with a target price of Rs 2660 in its research report dated May 12, 2017....

Dr Reddy's Labs Q4: Analysts see hope in US biz recovery, reduced regulatory concerns

3.54 pm | 15 May 2017 |  Source: Moneycontrol.com

Brokerages largely remain optimistic about the pharma major’s improvement in US business as well as reduced regulatory risks, while some also highli...

Buy, Sell, Hold: Here are 6 stocks that analysts are tracking today

9.03 am | 15 May 2017 |  Source: CNBC-TV18

Titan, Yes Bank, and Idea Cellular, among others, are on the radar of analysts on Monday....

Dr Reddy's Labs Q4 profit soars 175% on strong EM biz, misses earnings estimates

3.59 pm | 12 May 2017 |  Source: Moneycontrol.com

"FY17 has been a challenging year due to lack of new product approvals for the US market," said GV Prasad, chief executive officer and co-chairman of ...

Dr Reddy's Labs Q4 profit jumps 175%, operating income misses estimates 

1.23 pm | 12 May 2017 |  Source: Moneycontrol.com

Revenue during the quarter fell 4.8 percent to Rs 3,611.9 crore compared with Rs 3,795 crore in corresponding quarter of last fiscal....

Dr Reddy's Labs Q4 profit may jump over 5-fold but revenue seen down 2% 

12.51 pm | 12 May 2017 |  Source: CNBC-TV18

Revenue during the quarter may fall 2 percent year-on-year to Rs 3,680 crore due to lower US growth....

Stocks in the news: Kotak Bank, SBI, Axis Bank, Rel Infra, Asian Paints, Glenmark

8.21 am | 12 May 2017 |  Source: CNBC-TV18

Kotak Mahindra Bank | Axis Bank | Reliance Infrastructure | Asian Paints | Delta Corp | TVS Motor | Max India | Chembond Chemicals | Adhunik Power | N...

CNBC-TV18 accesses Form 483 received by DRL's Hyderabad unit 

8.25 am | 05 May 2017 |  Source: CNBC-TV18

Dr Reddy's Laboratories will also be on the radar today. United States Food and Drug Administration (USFDA) has issued Form 483 to DRL’s Hyderab...

Stocks in the news: Coal India, ONGC, SH Kelkar, Wockhardt, Amtek Auto, Strides 

8.13 am | 05 May 2017 |  Source: CNBC-TV18

ITC | Wipro | Coal India | ONGC | SH Kelkar | Wockhardt | Varun Beverages | Praj Industries | Strides Shasun | Amtek Auto | Oberoi Realty | Emami | II...

Dr Reddy's gets 11 observations from USFDA for Hyderabad plant

9.08 pm | 28 Apr 2017 |  Source: PTI

Drug major Dr Reddy’s Laboratories today said the US health regulator has issued 11 observations after inspecting its manufacturing plant in Hyderab...

Dr Reddy's launches cholesterol-lowering generic pill Vytorin in US 

3.38 pm | 27 Apr 2017 |  Source: Moneycontrol.com

The Vytorin brand had US sales of approximately USD 678 million for the most recent 12 months ended in February 2017, according to IMS Health....

Dr Reddy's Laboratories launches Ezetimibe and Simvastatin tablets in US market

10.27 am | 27 Apr 2017 |  Source: Moneycontrol.com

Dr Reddy's Laboratories has launched Ezetimibe and Simvastatin Tablets, 10mg/10mg, 10mg/20mg, 10mg/40mg, and 10mg/80mg, a therapeutic equivalent g...

USFDA observations for Dr Reddy's Srikakulam plant merely procedural 

10.14 pm | 25 Apr 2017 |  Source: CNBC-TV18

CNBC-TV18 accessed the form 483 which includes the two observations. While the first observation says that the pharma major's Srikakulam lab recor...

Dr Reddy’s Laboratories to announce Q4 results on May 12, 2017

2.40 pm | 25 Apr 2017 |  Source: Moneycontrol.com

Dr Reddy’s Laboratories will announce results for the fourth quarter and full year ended March 31, 2017 on May 12, 2017 after the board meeting....

1 2 3
Quick Links for Dr Reddys Laboratories
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.